Quantcast
Last updated on April 18, 2014 at 9:36 EDT

Latest Pharmaceutical companies Stories

2012-07-22 18:21:20

HOLZKIRCHEN, Germany, July 23, 2012 /PRNewswire/ -- Sandoz has completed its USD 1.525 billion acquisition of specialty US dermatology company Fougera Pharmaceuticals on a cash and debt free basis. Fougera had net sales of USD 429 million in 2011 in the US alone and, combined with Sandoz's existing generic dermatology franchise, this positions Sandoz as the new #1 in generic dermatology medicines both globally and in the US. Fougera has strong dermatology development and manufacturing...

2012-07-19 10:23:18

THOUSAND OAKS, Calif., July 19, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced that its Board of Directors today declared a $0.36 per share dividend for the third quarter of 2012. The dividend will be paid on Sept. 7, 2012, to all stockholders of record as of the close of business on Aug. 16, 2012. About AmgenAmgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new...

2012-07-19 02:25:07

To Support Development of Signature Neuroscience Exhibit PHILADELPHIA, July 19, 2012 /PRNewswire-USNewswire/ -- The Franklin Institute has received a $2.5 million contribution from leading global pharmaceutical company Teva Pharmaceuticals to develop a signature innovative exhibit at the museum exploring neuroscience and the human brain, entitled Your Brain. This contribution brings The Franklin Institute's Inspire Science fundraising campaign total to $65 million. (Logo:...

2012-07-18 18:20:40

TAINAN, Taiwan, July 18, 2012 /PRNewswire-Asia/ -- ScinoPharm (TWSE:1789) announced today that its Tainan, Taiwan Facility will provide commercial manufacturing of topiramate active pharmaceutical ingredient ("API") for VIVUS' Qsymia(TM), a new drug for the treatment of obesity approved by the United States Food and Drug Administration on July 17, 2012. Qsymia(TM) is the first FDA-approved once daily combination treatment for chronic weight management in adults who are obese or...

2012-07-18 02:26:44

NEW YORK, July 18, 2012 /PRNewswire/ -- Drugs.com, the leading online clinical drug resource, today released first quarter 2012 U.S. prescription sales data for the top 100 drugs. Blood-thinners, proton-pump inhibitors, antipsychotics and asthma therapeutic categories continue to remain top sellers. Top Five Drugs by Sales, Q1 2012 Drug Name Sales ($000) % Change (previous quarter) --------- ----------- ------------------...

2012-07-17 10:24:46

PITTSBURGH, July 17, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it and its subsidiary, Mylan Pharmaceuticals Inc., have entered into a settlement agreement with Somaxon Pharmaceutical, Inc. that will resolve the parties' patent litigation in connection with Mylan Pharmaceuticals' Abbreviated New Drug Application (ANDA) for Doxepin Hydrochloride Tablets, 3 mg and 6 mg, which is the generic version of Somaxon's Silenor®, indicated for the treatment of insomnia...

2012-07-17 06:26:57

SAN DIEGO, July 17, 2012 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the appointment of Daniel Ripley as Head of Corporate Development, effective immediately. Mr. Ripley will lead licensing, partnering initiatives, intellectual property analysis and act as the internal coordinator of the emricasan commercialization strategy development. "Dan brings experience in both in-licensing and out-licensing of commercial products as well as extensive experience in partnering...

2012-07-17 06:25:18

NEWTOWN, Pa., July 17, 2012 /PRNewswire/ -- Encuity Research, the market research and analytics subsidiary of Campbell Alliance, today released its Promotional Trends Report for July 2012, highlighting key product promotion trends within the pharmaceutical and biotech industry. This quarterly report leverages data from Encuity's syndicated market research suite to examine promotional activity, including mix and spend, across key therapeutic markets. The July 2012 Promotional Trends Report...

GSK Pharma Acquires Human Genome Sciences For $3.6 Billion
2012-07-17 09:45:58

Lawrence LeBlond for redOrbit.com - Your Universe Online British pharmaceutical giant GlaxoSmithKline (GSK) has acquired US-based Human Genome Sciences (HGS) after tough negotiations saw it raise offers from an initial $2.6 billion in April, putting the final value of the deal at $3.6 billion or $14.25 per share. By securing HGS, GSK is gaining full control of the drug Benlysta, the first drug in more than 50 years to be approved by the Food and Drug Administration (FDA) for the...

2012-07-16 02:24:23

SHANGHAI and DALIAN, China, July 16, 2012 /PRNewswire-USNewswire/ -- C3i, the leader in service desk support and business process outsourcing (BPO) services for the life sciences industry, announced today the appointment of Jonathan Song to business development executive in Asia. C3i provides end-user technology training, multi-lingual service desk and configuration and deployment for mobile application hardware, including iPad/iPhone to life science organizations worldwide. C3i works with...